3 stories this morning, for surgeons and the people who support them.
- Integra LifeSciences Q3: revenue $411.2M (+2.5% organic) with Neuro up 6.5% organic, Tissue Reconstruction down 2.2%, a ~$7M Cincinnati flood hit, lowered FY26 revenue guidance, and a $2.1B refinancing including $450M of 9.5% secured notes — October 21, 2026 earnings release (8-K Ex. 99.1): Q3 revenue $411.2M, +2.3% reported, +2.5% organic. Specialty Surgery $304.1M (+4.2% organic); Neuro +6.5% organic on CereLink, Certas Plus, Bactiseal, DuraSeal and recovery in cranial perforators; Tissue Reconstruction $107.1M (-2.2%). ~$7M Cincinnati flood revenue impact. FY26 revenue guidance $1.634-1.654B (reported -0.1% to +1.2%), adjusted EPS $2.30-2.40. $2.1B refinancing completed October 19 incl. $450M 9.5% senior secured notes due 2033. Braintree transition charges $8.8M in Q3; SurgiMend relaunch expected Q4 2026. Cross-checked against the orthospinenews.com reprint of the release. Source
- Total Joint Orthopedics takes a Wells Fargo debt facility of up to $11 million to fund implant inventory, instrument sets, distribution and its cobalt-chrome-free Aurum designs — Company release dated October 21, 2026 (Salt Lake City), also reported by ORTHOWORLD: debt facility of up to $11M from Wells Fargo, chosen over equity or a strategic partner to preserve ownership; funds go to implant inventory and instrument sets for hospitals and ASCs, distribution partners, porous and revision Aurum designs (multi-year plan to eliminate cobalt chrome), a next-generation Platform Hip stem and additive manufacturing. Klassic Knee: 42,000+ implanted, 12-year survivorship data cited by the company. Exhibiting at AAHKS, November 5-8, Grapevine, Texas. Terms not disclosed. Source
- JAMA, PELICAN RCT: individualized cardiac index-guided hemodynamic therapy did not reduce a 7-day composite of complications or death vs routine care in 1,095 high-risk patients having elective major abdominal surgery — Published online October 19, 2026 (PMID 42896534; NCT05648279). Multicenter single-blind superiority RCT at 12 university centers in Austria, Czech Republic, Denmark, Germany and Spain; 1,111 randomized, 1,095 analyzed. Targeting each patient's preoperative resting cardiac index vs routine therapy with blinded cardiac index monitoring. Primary composite (AKI, myocardial injury, severe infection, nonfatal cardiac arrest, death within 7 days): 44.3% vs 46.9%, RR 0.94 (95.1% CI 0.83-1.08), P=.38; no component differed. Lead author reports grants and fees from monitoring manufacturers including Edwards Lifesciences. Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.